SI3143011T1 - Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva - Google Patents

Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva

Info

Publication number
SI3143011T1
SI3143011T1 SI201531590T SI201531590T SI3143011T1 SI 3143011 T1 SI3143011 T1 SI 3143011T1 SI 201531590 T SI201531590 T SI 201531590T SI 201531590 T SI201531590 T SI 201531590T SI 3143011 T1 SI3143011 T1 SI 3143011T1
Authority
SI
Slovenia
Prior art keywords
heterocyclic compounds
imaging agents
deuterated
deuterated heterocyclic
imaging
Prior art date
Application number
SI201531590T
Other languages
English (en)
Slovenian (sl)
Inventor
Jan Marik
Joseph P. Lyssikatos
Simon Williams
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3143011T1 publication Critical patent/SI3143011T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201531590T 2014-05-13 2015-05-12 Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva SI3143011T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents
EP15725253.7A EP3143011B1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
SI3143011T1 true SI3143011T1 (sl) 2021-08-31

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531590T SI3143011T1 (sl) 2014-05-13 2015-05-12 Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3901145A1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102530129B1 (enExample)
CN (2) CN106459059B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX384604B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG10201805628TA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3143011T (pt) * 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
MX386900B (es) 2016-07-22 2025-03-19 Ac Immune S A Star Compuestos para formacion de imagenes de agregados de proteinas tau.
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
AU2017367872B2 (en) * 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
EP3758696A4 (en) 2018-03-02 2021-12-08 The Trustees of the University of Pennsylvania [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AND USE THEREOF TO STABILIZE MICROTUBULES
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
HRP20230409T1 (hr) 2018-10-05 2023-07-07 Forma Therapeutics, Inc. Fuzionirani pirolini koji djeluju kao inhibitori ubikvitin specifične proteaze 30 (usp30)
ES2976515T3 (es) 2018-10-05 2024-08-02 Annapurna Bio Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
TWI804079B (zh) 2019-05-09 2023-06-01 瑞士商赫孚孟拉羅股份公司 經標記之咪唑并[1,2-a]嘧啶之合成
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (enExample) *
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
BRPI0710225B1 (pt) 2006-03-30 2021-07-13 The Trustees Of The University Of Pennsylvania Derivados e composições de estirilpiridina compreendendo os mesmos
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
KR20100135235A (ko) 2008-02-14 2010-12-24 지멘스 메디컬 솔루션즈 유에스에이, 인크. 신경학적 기능이상을 검출하기 위한 조영제
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102438660A (zh) 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
EP2450332A1 (en) 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
MX2013005478A (es) * 2010-11-15 2013-08-29 Univ Leuven Kath Compuestos heterociclicos condensados antivirales.
KR101609504B1 (ko) * 2012-05-22 2016-04-05 일라이 릴리 앤드 캄파니 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제
NO3055308T3 (enExample) * 2013-10-08 2018-04-21
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia

Also Published As

Publication number Publication date
AU2015261008B2 (en) 2019-02-14
MX384604B (es) 2025-03-14
KR102618139B1 (ko) 2023-12-27
DK3143011T3 (da) 2021-05-03
NZ726208A (en) 2023-11-24
JP2017515856A (ja) 2017-06-15
MX376163B (es) 2025-03-07
JP2019147825A (ja) 2019-09-05
US11504440B2 (en) 2022-11-22
IL280791A (en) 2021-04-29
ES2867814T3 (es) 2021-10-20
AU2019203369B2 (en) 2020-06-04
IL280791B2 (en) 2024-03-01
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
CN106459059A (zh) 2017-02-22
US10675367B2 (en) 2020-06-09
US20160250358A1 (en) 2016-09-01
IL271631B (en) 2021-05-31
KR20230035445A (ko) 2023-03-13
HRP20210641T1 (hr) 2021-05-28
KR102530129B1 (ko) 2023-05-10
CA2948721C (en) 2023-03-28
LT3143011T (lt) 2021-05-10
PL3143011T3 (pl) 2021-07-19
HUE053939T2 (hu) 2021-08-30
IL248692A0 (en) 2017-01-31
US20230218782A1 (en) 2023-07-13
US10076581B2 (en) 2018-09-18
MX2020010847A (es) 2021-07-16
PT3143011T (pt) 2021-04-26
RS61810B1 (sr) 2021-06-30
MX2016014615A (es) 2017-03-06
SG11201609281UA (en) 2016-12-29
AU2019203369A1 (en) 2019-06-06
WO2015173225A1 (en) 2015-11-19
CA2948721A1 (en) 2015-11-19
EP3143011B1 (en) 2021-03-03
BR112016026443A2 (pt) 2017-08-15
CN110483522A (zh) 2019-11-22
EP3901145A1 (en) 2021-10-27
IL271631A (en) 2020-02-27
US20200297875A1 (en) 2020-09-24
US20190201561A1 (en) 2019-07-04
EP3143011A1 (en) 2017-03-22
IL248692B (en) 2020-01-30
JP6529986B2 (ja) 2019-06-12
NZ764181A (en) 2023-11-24
RU2016147742A3 (enExample) 2018-10-08
JP6681498B2 (ja) 2020-04-15
CN110483522B (zh) 2022-05-03
US12214058B2 (en) 2025-02-04
KR20170002639A (ko) 2017-01-06
IL280791B1 (en) 2023-11-01
AU2015261008A1 (en) 2016-11-17
BR112016026443A8 (pt) 2021-07-06
CN106459059B (zh) 2019-09-24
RU2016147742A (ru) 2018-06-18

Similar Documents

Publication Publication Date Title
IL248692B (en) Heterocyclic compounds containing deuterium and their use as imaging agents
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
GB201403093D0 (en) Therapeutic compounds and their use
IL247599A0 (en) Formulation that suppresses the immune system
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
PL3194421T3 (pl) Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania
ZA201701312B (en) Novel imidazopyridazine compounds and their use
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
PL3268356T3 (pl) Związki heterocykliczne i sposoby ich stosowania
GB201420795D0 (en) Super sponge
GB201420506D0 (en) Fresh "N" up
GB201613134D0 (en) Novel compounds and their use
GB201413411D0 (en) Novel compounds and their use
GB201514770D0 (en) Compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201411907D0 (en) Targeted imaging agent